Chairman and CEO Richard Pops told attendees at the 2026 TD Cowen Healthcare Conference that the company entered 2026 with ...

If you are wondering whether Alkermes at around US$27.64 is pricing in its full potential or leaving some room on the table, ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Alkermes, with a price target of $43.00. Amsellem covers the Healthcare sector, focusing on stocks such as ...

(Reuters) -Alkermes said on Wednesday it will acquire Avadel Pharmaceuticals in a deal valued at up to $2.1 billion, gaining an approved sleep-disorder treatment and expanding into the sleep medicine ...

Avadel PharmaceuticalsAVDL stock jumped Wednesday, and AlkermesALKS shares recovered somewhat from a steep dive, after the latter agreed to buy the former for up to $2.1 billion. Evercore ISI analyst ...

As stripped down and divested Alkermes enters 2024 as a “pure-play neuroscience company”—as described by CEO Richard Pops on a conference call on Thursday—much will depend on the success of new ...

Alkermes (NASDAQ:ALKS) is gearing up to announce its quarterly earnings on Thursday, 2024-10-24. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...

— Competitive Grant Program to Offer Individual Grants of Up to $10,000 per Project — — Inaugural Application Cycle Open to Licensed Psychiatric-Mental Health Nurse Practitioners Across Multiple ...

Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Tuesday, March 17, 2026 at 8:30 a.m. ET (12:30 p.m. GMT). The ...